Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
1.2.1. Overactive Bladder Treatment Market, by Region, 2019-2027 (USD Billion)
1.2.2. Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2027 (USD Billion)
1.2.3. Overactive Bladder Treatment Market, by Disease type, 2019-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Overactive Bladder Treatment Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Overactive Bladder Treatment Market Dynamics
3.1. Overactive Bladder Treatment Market Impact Analysis (2019-2027)
3.1.1. Market Drivers
3.1.1.1. Assertive Marketing By Pharma Companies
3.1.1.2. Development of Innovative Intravesical Therapies
3.1.2. Market Restraint
3.1.2.1. Undesired Systemic Effects of Current OAB Treatments
3.1.3. Market Opportunities
3.1.3.1. Novel Treatments, Robust Pipeline, and Patent Cliff of Certain Drugs
3.1.3.2. increasing occurrences of Parkinson's disease, and multiple sclerosis and stroke
Chapter 4. Global Overactive Bladder Treatment Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Overactive Bladder Treatment Market , by Pharmacotherapy
5.1. Market Snapshot
5.2. Global Overactive Bladder Treatment Market by Pharmacotherapy , Performance - Potential Analysis
5.3. Global Overactive Bladder Treatment Market Estimates & Forecasts by Pharmacotherapy 2018-2027 (USD Billion)
5.4. Overactive Bladder Treatment Market , Sub Segment Analysis
5.4.1. Anticholinergics
5.4.2. Solifenacin
5.4.3. Oxybutynin
5.4.4. Darifenacin
5.4.5. Fesoterodine
5.4.6. Others
Chapter 6. Global Overactive Bladder Treatment Market , by Disease type
6.1. Market Snapshot
6.2. Global Overactive Bladder Treatment Market by disease Type, Performance - Potential Analysis
6.3. Global Overactive Bladder Treatment Market Estimates & Forecasts by disease type 2018-2027 (USD Billion)
6.4. Overactive Bladder Treatment Market , Sub Segment Analysis
6.4.1. Idiopathic Bladder Overactivity
6.4.2. Neurogenic Bladder Overactivity
Chapter 7. Global Overactive Bladder Treatment Market , Regional Analysis
7.1. Overactive Bladder Treatment Market , Regional Market Snapshot
7.2. North America Overactive Bladder Treatment Market
7.2.1. U.S. Overactive Bladder Treatment Market
7.2.1.1. Pharmacotherapy breakdown estimates & forecasts, 2018-2027
7.2.1.2. Disease type breakdown estimates & forecasts, 2018-2027
7.2.2. Canada Overactive Bladder Treatment Market
7.3. Europe Overactive Bladder Treatment Market Snapshot
7.3.1. U.K. Overactive Bladder Treatment Market
7.3.2. Germany Overactive Bladder Treatment Market
7.3.3. France Overactive Bladder Treatment Market
7.3.4. Spain Overactive Bladder Treatment Market
7.3.5. Italy Overactive Bladder Treatment Market
7.3.6. Rest of Europe Overactive Bladder Treatment Market
7.4. Asia-Pacific Overactive Bladder Treatment Market Snapshot
7.4.1. China Overactive Bladder Treatment Market
7.4.2. India Overactive Bladder Treatment Market
7.4.3. Japan Overactive Bladder Treatment Market
7.4.4. Australia Overactive Bladder Treatment Market
7.4.5. South Korea Overactive Bladder Treatment Market
7.4.6. Rest of Asia Pacific Overactive Bladder Treatment Market
7.5. Latin America Overactive Bladder Treatment Market Snapshot
7.5.1. Brazil Overactive Bladder Treatment Market
7.5.2. Mexico Overactive Bladder Treatment Market
7.6. Rest of The World Overactive Bladder Treatment Market
Chapter 8. Competitive Intelligence
8.1. Top Market Strategies
8.2. Company Profiles
8.2.1. Intas Pharmaceuticals Ltd.
8.2.1.1. Key Information
8.2.1.2. Overview
8.2.1.3. Financial (Subject to Data Availability)
8.2.1.4. Product Summary
8.2.1.5. Recent Developments
8.2.2. Teva Pharmaceutical Industries Limited
8.2.3. Aurobindo Pharma Limited
8.2.4. Hisamitsu Pharmaceutical Co., Inc.
8.2.5. Johnson & Johnson
8.2.6. Macleods Pharmaceuticals Ltd.
8.2.7. Endo International PLC
8.2.8. Mylan N.V.
8.2.9. Apotex Inc.
8.2.10. Allergan, PLC.
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption